What Is Fatty Liver Disease and Why It's So Common
Fatty liver disease — now officially called MASLD — affects nearly 40% of the global population, yet most people don't know they have it. Here's how it develops, what makes it dangerous, and what medicine can now do about it.
A Silent Epidemic in Plain Sight
It causes no pain, rarely triggers symptoms, and is almost never caught until it has quietly advanced for years. Yet metabolic dysfunction-associated steatotic liver disease — known by its acronym MASLD, and formerly called nonalcoholic fatty liver disease (NAFLD) — is now one of the most prevalent chronic conditions on the planet, estimated to affect nearly 40% of the global population. In the United States alone, roughly one in three adults is believed to have it.
The condition is so widespread, and so tightly linked to obesity and diabetes, that researchers describe it as the liver's version of metabolic syndrome. Understanding how it works — and what can be done — has never been more urgent.
What Actually Happens in the Liver
The liver is the body's metabolic powerhouse, processing nutrients, filtering toxins, and regulating blood sugar. When the body becomes resistant to insulin — a hallmark of obesity, type 2 diabetes, and poor diet — fat starts accumulating inside liver cells as droplets of triglycerides. This early, non-inflammatory stage is called simple steatosis, or a fatty liver.
By itself, simple steatosis is relatively benign. The liver is enlarged and fatty, but liver function remains mostly intact. The danger lies in what can come next.
In somewhere between 7% and 30% of people with fatty liver, the accumulation of fat triggers an inflammatory cascade. Immune cells flood the liver, and the organ becomes swollen and damaged — a condition now called MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH). MASH is where the real risk begins.
The Four Stages
MASLD follows a clear but insidious progression:
- Steatosis: Fat accumulates in liver cells. Usually asymptomatic and reversible with lifestyle changes.
- MASH (steatohepatitis): Inflammation and liver cell damage begin. Fatigue may appear. This stage significantly raises the risk of long-term harm.
- Fibrosis: Scar tissue forms as the liver tries to repair itself. Blood flow becomes restricted. This stage can still be slowed or partially reversed.
- Cirrhosis: Widespread scarring replaces healthy liver tissue. Liver function declines sharply, and the risk of liver cancer rises dramatically. At least one-third of people with MASH eventually reach cirrhosis.
Who Is Most at Risk?
MASLD does not discriminate by age, but certain groups face far higher odds. The condition is present in 80–90% of obese adults, in 30–50% of people with type 2 diabetes, and in more than 90% of patients with high blood lipids (hyperlipidemia), according to research published in StatPearls via the National Institutes of Health.
Children are not immune: fatty liver disease affects up to 40–70% of children with obesity, making it the most common chronic liver condition in pediatric populations in high-income countries.
Genetic factors also matter. Variants in genes like PNPLA3 raise susceptibility significantly, which partly explains why some lean individuals also develop the disease.
Diagnosis: Often Missed Until Late
Because MASLD rarely causes pain or obvious symptoms in early stages, it is frequently discovered by accident — through a routine blood test showing elevated liver enzymes, or an ultrasound performed for another reason. The gold standard for staging the disease is a liver biopsy, though non-invasive tests using ultrasound elastography and blood biomarkers are increasingly used to avoid that procedure, according to Johns Hopkins Medicine.
Treatment: Lifestyle First, Now With a Drug Option
For most of its history, MASLD had no approved pharmaceutical treatment. The primary prescription was weight loss, a healthier diet, and regular exercise — which, if achieved, can genuinely reverse early-stage disease. Losing just 5–10% of body weight can meaningfully reduce liver fat.
That changed in 2025, when the FDA approved Wegovy (semaglutide) for adults with MASH and moderate-to-advanced liver fibrosis — making it one of the first drugs specifically cleared for this condition. In the Phase 3 ESSENCE trial, 63% of participants on semaglutide achieved MASH resolution without worsening fibrosis, compared to 34% on placebo, as reported by the U.S. Food and Drug Administration.
Resmetirom, a thyroid receptor agonist targeting liver cells directly, became the first approved MASH drug earlier in 2024. Together, these approvals mark a turning point after decades when lifestyle change was the only real option.
Why the Name Changed — and Why It Matters
In 2023, a global panel of hepatology experts voted to rename NAFLD to MASLD, replacing the word "fatty" — deemed stigmatizing — with "steatotic," while centering the name on metabolic dysfunction. The change, detailed by the American Liver Foundation, reflects a broader shift: this is no longer seen merely as a disease of excess, but as a metabolic condition with complex genetic, dietary, and environmental roots that deserves the same clinical attention as heart disease or diabetes.
With prevalence still rising and millions undiagnosed, that attention is long overdue.
